World Evidence, Pricing, and Access Conference 2024
Amstersdam, Netherlands
Regression-based forecasting can be used to inform launch pricing, contracting strategy, and competitive positioning
There is no doubt that anti-PD-1 drugs changed cancer care forever, but as products, they are still subject to competitive forces.
With the Medicare Negotiation Program set to begin in 2026, Keytruda and Opdivo face competitive threats from new entrants/loss of exclusivity and strong market entry of ADCs.
In this illustrative example, we see that the U.S. is a great example to show what the social security system bears versus the commercial market.
Spend less time going back over articles and make documentation easier.
Markov models + decision trees + state transitions --> microsimulation --> dynamic models
A market researchers perspectives on today's global market access in Pharma
Do you remember when HIPAA-compliance was a contentious topic? All patient data is de-identified quickly
